“I’m frightened of what the cancer might do to me. I’m also frightened of what the treatment might do to me. And somehow I’m supposed to make a clear decision while I’m carrying both fears.”
Perhaps you recognise that feeling. You leave the appointment with a treatment name written down. Later, sitting at the kitchen table, you realise that the question you most wanted to ask is still there.
What might happen if I have this chemotherapy, and what might happen if I don’t?
You may be thinking about whether you’ll feel well enough to work, pick up the grandchildren, or sit at the dinner table and enjoy the company of people you love. You may be afraid that treatment will make you feel less like yourself. You may also be afraid that, if you decline it, the cancer could progress or come back and you’ll wonder whether chemotherapy might have helped.
Those fears can sit side by side. You can care deeply about living longer and care deeply about what your days feel like. If someone you love is coming to the appointment, it may help to tell them what you’re most afraid to ask. They can write down the answer while you listen.
The questions below give you a way to compare the two paths using the details of your diagnosis and the treatment you’ve actually been offered. Start with whichever question is keeping you awake.
How to use the side-by-side comparison
Start by writing down the name of the chemotherapy or combination of drugs being offered. Ask your oncologist to describe what your care would look like if you chose that treatment and what care would be available if you chose to go without it. Depending on your situation, the other path could include a different cancer treatment, follow-up with planned monitoring, or care focused on managing symptoms. You need to know what each path involves before you can compare them. [1]
Then take one question at a time. When someone gives you a number, ask what it measures, who it comes from and how long people were followed. If you’re comparing two numbers, ask for both out of 100 people, over the same period. When an estimate is uncertain, write down what’s uncertain. That might be how closely the study matches your situation, whether it looked at the drugs you’ve been offered, or whether it followed people for long enough. [2, 3]
If the conversation starts moving too quickly, you could say, “Can we pause there? I want to make sure I understand what those two options would mean for me.”
Six questions to take to your appointment
On a narrow screen, scroll across the table to see both options. The six questions are also explained below.
| Question | If I have this chemotherapy | If I don’t have this chemotherapy |
|---|---|---|
| 1. What are we trying to achieve? | What is the main goal of this treatment for me? | What would my other options aim to achieve? |
| 2. How much difference might it make? | Out of 100 people like me, how many might reach that goal with this treatment, and over what period? | Out of 100 similar people, how many might reach the same goal over the same period with the care I’d otherwise receive? |
| 3. How many people like me might be alive in five years? | Out of 100 people with a diagnosis like mine, how many would you expect to be alive in five years with this chemotherapy as part of their care? | Out of 100 similar people, how many would you expect to be alive in five years with the care I’d otherwise receive? |
| 4. What might everyday life look like? | What would a typical treatment cycle involve? Which side effects are likely, which might last, and what help would I have? | What symptoms or changes might I experience from the cancer or the other care I receive? What help would I have? |
| 5. What if things change? | How would we assess whether treatment is helping? What are my options if I’m struggling with side effects? | If I reconsider later, could the same treatment still be an option? What might change while I wait? |
| 6. What matters most to me? | What potential benefit would make the time, disruption and risks feel worthwhile to me? | What would matter most to me about this path, and which trade-offs would be hardest to accept? |
1. What are we trying to achieve?
The word treatment can cover several different goals. Chemotherapy may be offered as part of a plan aimed at curing cancer. After surgery, it may be offered to lower the chance of the cancer coming back. In other situations, the aim may be to slow its growth, give someone more time, ease symptoms, or achieve a combination of those goals. Ask your oncologist to put the main goal for your situation into one sentence. [1, 4]
You might ask, “If this goes as well as we reasonably hope, what would be different for me?” The answer might be about the chance of a recurrence in future years, the likelihood of feeling better in the coming months, or how long the cancer might be controlled. Then ask the same question about the other option. If you’re being offered several treatments together, ask what chemotherapy is expected to add to the plan. You may find that one part of the plan is doing something quite different from another.
2. How much difference might it make?
If you hear that a treatment “cuts the risk by a third,” ask what that means out of 100 people. Here is a made-up example to show the arithmetic. Suppose 15 out of 100 people experience a recurrence over a given period with one option and 10 out of 100 with another. Both statements describe that comparison:
- The recurrence risk is about one-third lower. That’s the relative reduction.
- Five fewer people out of 100 experience a recurrence. That’s the absolute difference.
Hearing both versions gives you a clearer picture of the size of the benefit. You can use the same approach to ask about harms. If a side effect concerns you, ask how many people out of 100 experience it, how severe it tends to be, and whether the team has figures for your particular drugs. [2]
One question worth writing down is “What evidence are you using for those estimates, and how closely do the people in that research match me?” Your cancer subtype, stage, test results, other health conditions and previous treatments may affect how well a study applies. If your oncologist can give only a broad range, ask what puts someone toward either end of that range. [1, 3]
3. How many people like me might be alive in five years?
If living longer is one of the goals you want to weigh, you can ask directly about five-year overall survival. In plain English, you’re asking how many people were alive five years after a specified starting point, regardless of the cause of death. Ask when the clock starts in the figures you’re given. It could be the date of diagnosis, surgery or entry into a trial. Use the same starting point when you compare the two options. [3]
You can say, “Out of 100 people with a diagnosis like mine, how many would you expect to be alive in five years with this plan? How many with the care I’d otherwise receive? What’s the difference, and how sure are we?”
Sometimes there isn’t a reliable five-year comparison for the exact decision you’re facing. The closest study may have measured recurrence, how long the cancer stayed stable, or how well symptoms were controlled. Ask which outcomes were actually measured, how long people were followed, and whether the study tells us anything about overall survival. If your main concern is how you might feel or function in the next few months, ask what the evidence says about that as well. [3]
4. What might everyday life look like?
A list of side effects can feel overwhelming when you’re trying to picture an ordinary week. Ask your team to walk you through one cycle. How often would you go to the clinic? What might the first few days feel like? How much can experiences vary from person to person and from one cycle to the next? Would you need someone to drive you or help at home? [4, 5]
Then name the concern that matters most to you. You might worry about fatigue, hair loss, nausea, infection, concentration or nerve symptoms. Ask which are relevant to the drugs you’ve been offered, what can be done to reduce or manage them, and which could persist after treatment. You can also ask for the written information sheet for your specific regimen and check who to call after hours if you become unwell. [4, 5]
Give the other path the same attention. If you would receive another treatment, ask about its likely burdens and side effects. If the plan is monitoring or symptom-focused care, ask what changes your team would look for, how often you’d check in, and what help would be available if symptoms developed. Under either option, you can ask, “What support would I and the people helping me have on an ordinary week?” [1, 4]
5. What if things change?
Before starting, ask how the team will assess what is happening and what decisions might come up along the way. Depending on the goal, that could mean reviewing symptoms, scans or blood tests. If chemotherapy is being given after surgery to reduce the chance of recurrence, there may be no visible tumour to measure. Ask what follow-up can tell you in your situation. [4, 5]
If you find treatment harder to manage than you expected, would a delay, dose change or different plan be possible? Who would you speak to, and how would you weigh what a change might mean for the expected benefit? If your first choice is to go without the proposed chemotherapy, ask what the follow-up plan would be and under what circumstances you might revisit that decision. [1, 4, 5]
If you want time to think or get a second opinion, ask about timing in concrete terms. “What is the medically reasonable time frame for making this decision in my case? What, if anything, might change if I took enough time to speak with another specialist?” Cancer Australia has a practical guide to arranging a second opinion. [6]
6. What matters most to me?
You might care most about having every reasonable chance of more time. You might have a particular concern about remaining independent, continuing to work, or being able to care for someone who depends on you. You might be willing to manage a difficult period if it’s likely to be temporary and feel differently about a side effect that could last. These are things your care team needs to hear to understand what the choice means in your life. [1, 2]
Try saying what matters to you as plainly as you can. “I’m willing to consider a hard few months. What I’m most worried about is losing the ability to do the things that make my life feel like mine.” Or, “I want to know what this might do for my chance of being here in five years, because that’s what weighs most heavily for me.”
If you’re afraid of how your family might feel, give them a chance to tell you in their own words. You might ask, “Can you listen while I talk through the two options? What I need most today is help sorting through the information.”
What the Australian and US study tells us
A 2004 paper by Graeme Morgan, Robyn Ward and Michael Barton looked at the contribution of cytotoxic chemotherapy to five-year survival across 22 adult cancers. The researchers combined published treatment evidence with 1998 cancer registry data. Their model estimated that the additional five-year survivors attributable to curative or adjuvant cytotoxic chemotherapy represented 2.3% of all diagnoses studied in Australia and 2.1% in the United States. [7]
The words all diagnoses studied matter. The researchers counted a whole diagnosed population, which included people who wouldn’t have been offered chemotherapy and people who never received it. So if you’ve seen those figures described as a roughly 97% failure rate among people who took chemotherapy, that interpretation uses a different group of people from the one the study counted. The paper focused on being alive at five years. It didn’t estimate the overall effect on symptoms or quality of life. [7]
Later human research shows why it’s worth asking about the exact treatment being offered. A 2023 analysis of randomised trials in early breast cancer found that some chemotherapy regimens reduced recurrence more than others. In a different comparison, the TAILORx randomised trial found similar outcomes with hormone therapy alone and with hormone therapy plus chemotherapy across the overall group it randomised. Some women aged 50 or younger appeared to benefit from adding chemotherapy. The trial involved a specific type of early breast cancer and a defined range of genomic test scores. The two studies asked different questions in different groups. [8, 9]
If the 2004 paper is the reason you started asking questions, bring that curiosity to the conversation. “Can you show me the evidence closest to my situation and explain what it says about the choice I’m facing now?”
Before you leave the appointment
If you want something simple to take with you, write down the name of the proposed treatment, its main goal, and the care you’d receive if you went without it. Mark the question you most want answered. You can start there even if you never get through the rest of the list.
Before you leave, read your understanding back to the clinician. You might say, “Let me check I’ve understood. This is what you hope chemotherapy will do. This is what you expect if I go without it. And this is the part you can’t tell me with much certainty. Have I got that right?” [2]
Two lines to take home
What I know now is …
What I still need to know before I can decide is …
You may leave with a clearer sense of which option fits what matters to you. You may leave knowing exactly which question you need to ask next. If you can name that question and know who to ask, you have something concrete to take into the next conversation.
Explore A — Ask Better Questions on the C.A.L.M. Resources page.
Informed by Evidence — Guided by Love.
Sources and further reading
- Cancer Australia — Choosing a cancer treatment
- NICE — Shared decision making, including how to discuss risks and benefits
- US National Cancer Institute — Understanding cancer prognosis and survival statistics
- Cancer Council NSW — Chemotherapy and questions for your doctor
- eviQ — Common questions about chemotherapy
- Cancer Australia — Getting a second opinion
- Morgan, Ward and Barton, 2004 — The contribution of cytotoxic chemotherapy to five-year survival in adult malignancies
- Early Breast Cancer Trialists’ Collaborative Group, 2023 — Patient-level analysis of anthracycline- and taxane-containing chemotherapy for early breast cancer
- Sparano and colleagues, 2018 — TAILORx trial of adjuvant chemotherapy guided by a 21-gene test




